Investigational drug · Phase 2
M6223
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced or Metastatic Urothelial Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "M6223"
First trial start
2022
Aug 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "M6223", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic Urothelial Carcinoma
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "M6223" as an intervention, largest first.
- A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Pivotal-lookingActive, not recruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT05327530 · 256 participants · Start Aug 17, 2022 · Primary completion Jun 20, 2025
Drug: Avelumab; Sacituzumab Govitecan (SG) and 3 more · For: Locally Advanced or Metastatic Urothelial Carcinoma
Sites: Coeur d'Alene, Idaho; Kansas City, Kansas; Baltimore, Maryland · 98 sites in all
- First in Human Study of M6223Completed
EMD Serono Research & Development Institute, Inc.Industry
NCT04457778 · 58 participants · Start Jul 10, 2020 · Primary completion Jun 23, 2023
Drug: M6223; Bintrafusp alfa and 1 more · For: Metastatic Solid Tumors
Sites: Nashville, Tennessee; Houston, Texas; San Antonio, Texas · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Model-Informed Selection of the Recommended Phase 2 Dosage for Anti-TIGIT Immunotherapy Leveraging co-Expressed PD-1 Inhibitor Target Engagement.
Kareva I, Hu P, Pierre V, et al. · Clin Pharmacol Ther 2025
- TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial.
Naing A, McKean M, Tolcher A, et al. · J Immunother Cancer 2025
- The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
Hoffman-Censits J, Grivas P, Powles T, et al. · Future Oncol 2024
Also in development for Locally Advanced or Metastatic Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.